SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Marksans Pharma - Quaterly Results

12 Nov 2024 Evaluate
A decent increase of about 50.79% in the turnover to Rs. 3086.25 millions was observed for the quarter ended September 2024. The turnover stood at Rs. 2046.73 millions during the similar quarter previous year.The company almost doubled its revenue to Rs. 632.04 millions  from Rs. 312.89 millions in the quarter ended September 2024.Operating profit for the quarter ended September 2024 rose to 836.29 millions as compared to 532.30 millions of corresponding quarter ended September 2023.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202409 202309 % Var 202409 202309 % Var 202403 202303 % Var
Sales 3086.25 2046.73 50.79 5631.52 3867.14 45.62 8532.73 6552.04 30.23
Other Income 313.57 159.31 96.83 395.09 485.54 -18.63 620.73 604.82 2.63
PBIDT 836.29 532.30 57.11 1330.47 1126.11 18.15 2020.08 1523.85 32.56
Interest 2.76 2.31 19.48 5.59 4.93 13.39 9.88 36.13 -72.65
PBDT 833.53 529.99 57.27 1324.88 1121.18 18.17 2010.20 1487.72 35.12
Depreciation 70.16 84.98 -17.44 138.52 132.22 4.76 291.28 167.37 74.03
PBT 763.37 445.01 71.54 1186.36 988.96 19.96 1718.92 1320.35 30.19
TAX 131.33 132.12 -0.60 234.17 234.16 0.00 381.34 291.69 30.73
Deferred Tax 5.22 15.36 -66.02 4.48 42.30 -89.41 6.78 -1.71 -496.49
PAT 632.04 312.89 102.00 952.19 754.80 26.15 1337.58 1028.66 30.03
Equity 453.16 453.16 0.00 453.16 453.16 0.00 453.16 45316.00 -99.00
PBIDTM(%) 27.10 26.01 4.19 23.63 29.12 -18.87 23.67 23.26 1.79

Marksans Pharma Share Price

180.50 1.60 (0.89%)
16-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1693.15
Dr. Reddys Lab 1221.25
Cipla 1230.75
Zydus Lifesciences 939.20
Lupin 2326.50
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×